Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of Antiplatelets in Psoriasis
Sponsor: NYU Langone Health
Summary
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
Official title: A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-09
Completion Date
2031-09
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
Aspirin
81 mg capsule orally once daily for 4 weeks
Clopidogrel
75 mg capsule orally once daily for 4 weeks
Placebo
Matching placebo (microcellulose powder) capsule orally once daily for 4 weeks
Locations (1)
NYU Langone Health
New York, New York, United States